Unfractionated Heparin for the Treatment of Venous Thromboembolism: Best Practices and Areas of Uncertainty

被引：19
|
作者：
Cuker, Adam [1 ,2 ]
机构：
[1] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
来源：
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2012年 / 38卷 / 06期
关键词：
heparin; unfractionated heparin; venous thromboembolism; dosing; laboratory monitoring; PARTIAL THROMBOPLASTIN TIME; MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; CONTINUOUS INTRAVENOUS HEPARIN; ACUTE PULMONARY-EMBOLISM; MYOCARDIAL-INFARCTION; ANTICOAGULANT-THERAPY; SUBCUTANEOUS HEPARIN; INITIAL TREATMENT; ANTITHROMBIN-III;
D O I：
10.1055/s-0032-1319770
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Nearly 100 years after its discovery, unfractionated heparin (UFH) remains a widely used anticoagulant for the treatment of venous thromboembolism (VTE) and several other thrombotic and prothrombotic conditions. Decades of experience and investigation have contributed to our knowledge of this agent, but crucial questions regarding its optimal use in clinical practice remain unanswered. This review will critically examine the evidence for dosing and laboratory monitoring of UFH in the management of VTE, and highlight areas of uncertainty and future research.
引用
收藏
页码：593 / 599
页数：7
相关论文
共 50 条
12345